Luca De Fiore, Chief Executive Officer of Il Pensiero Scientifico Editore, shared a post on LinkedIn:
“Going beyond Conflict of Interest disclosure
In the days of the great circus of oncology in ESMO, Ian Tannock and Saroj Niraula address a critical issue for research, health and governance on the Journal of Clinical Oncology: it is not enough to declare a conflict of interest, but it is necessary to avoid them and promote integrity and trust in research by citizens.
More than 70% of the trials published in the JCO that evaluate a health intervention include at least one author who has received compensations from the manufacturing company; Among lead authors (first or last), the percentage is 62%.
More than 90% of randomized phase III trials are funded by a company.
Around 80% of the reports and even abstracts presented at major cancer congresses acknowledge the contribution of a medical writer provided by industry.
The disclosure can give a sense of transparency, but it does not ensure that the contents are free from conditioning: structural solutions are needed.
Only by making health care independent of industry will oncology (and others) be able to regain the trust of the citizens.”
Title: Conflict of Interest: Moving From Disclosure to Avoidance
Authors: Ian Tannock, Saroj Niraula
Read the Full Article on Journal of Clinical Oncology
More posts featuring Luca De Fiore.